Stocks Health care CLLS
NASDAQ · Health careCellectis S.A. (CLLS)
Cellectis S.A. reported revenue of $72.9M in fiscal 2025, up 75.8% from a year earlier. It posted a net loss of $67.6M. In fiscal 2025 capital spending exceeded operating cash flow by $41.8M. At December 31, 2025 it held $61.5M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 20, 2026.
What Cellectis S.A. does
Cellectis S.A. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CLLS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $72.9M | -$67.6M | -$0.67 | -$41.8M |
| 2024 | $41.5M | -$36.8M | -$0.41 | $20.4M |
| 2023 | $755K | -$101.1M | -$1.77 | -$25.8M |
| 2022 | $19.2M | -$106.1M | -$2.33 | -$89.9M |
| 2021 | $30.3M | -$114.2M | -$2.55 | -$123.1M |
| 2020 | $51.1M | -$81.1M | -$1.91 | -$124.3M |
Latest SEC filings
What Cellectis S.A. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 14, 2026
- September 11, 2026
- September 11, 2026
- September 1, 2026
- August 6, 2026
- August 6, 2026
- August 6, 2026
- July 30, 2026
- June 26, 2026
- June 25, 2026
Questions about CLLS
What does Cellectis S.A. do?
Cellectis S.A. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CLLS.
Is Cellectis S.A. profitable?
No. In fiscal 2025 it reported a net loss of $67.6M on revenue of $72.9M.
How much revenue does Cellectis S.A. make?
In fiscal 2025 Cellectis S.A. reported revenue of $72.9M. That is 75.8% more than a year earlier.
When did Cellectis S.A. last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 20, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 14, 2026.
Similar companies
Follow CLLS
Get an email when Cellectis S.A. files with the SEC: results, executive changes, material agreements and annual reports.
Follow CLLS: get an email when it filesWhere the numbers come from
Financial figures are the values Cellectis S.A. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.